These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39073797)

  • 1. Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations.
    Diao JA; Shi I; Murthy VL; Buckley TA; Patel CJ; Pierson E; Yeh RW; Kazi DS; Wadhera RK; Manrai AK
    JAMA; 2024 Sep; 332(12):989-1000. PubMed ID: 39073797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherosclerotic Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations.
    Anderson TS; Wilson LM; Sussman JB
    JAMA Intern Med; 2024 Aug; 184(8):963-970. PubMed ID: 38856978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines.
    Pagidipati NJ; Navar AM; Mulder H; Sniderman AD; Peterson ED; Pencina MJ
    JAMA; 2017 Apr; 317(15):1563-1567. PubMed ID: 28418481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey.
    Gupta K; Kakar TS; Jain V; Gupta M; Al Rifai M; Slipczuk L; Nambi V; Bittner V; Blumenthal RS; Stone NJ; Lavie CJ; Virani SS
    Prog Cardiovasc Dis; 2022; 75():78-82. PubMed ID: 36038004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
    Qureshi WT; Kaplan RC; Swett K; Burke G; Daviglus M; Jung M; Talavera GA; Chirinos DA; Reina SA; Davis S; Rodriguez CJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28495699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort.
    Kavousi M; Leening MJ; Nanchen D; Greenland P; Graham IM; Steyerberg EW; Ikram MA; Stricker BH; Hofman A; Franco OH
    JAMA; 2014 Apr; 311(14):1416-23. PubMed ID: 24681960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study.
    Mortensen MB; Nordestgaard BG; Afzal S; Falk E
    Eur Heart J; 2017 Feb; 38(8):586-594. PubMed ID: 28363217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin Eligibility, Coronary Artery Calcium, and Subsequent Cardiovascular Events According to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis).
    Miedema MD; Dardari ZA; Kianoush S; Virani SS; Yeboah J; Knickelbine T; Sandfort V; Rodriguez CJ; Nasir K; Blaha MJ
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29899017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study.
    Khera R; Lu Y; Lu J; Saxena A; Nasir K; Jiang L; Krumholz HM
    BMJ; 2018 Jul; 362():k2357. PubMed ID: 29997129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study.
    Shah RV; Spahillari A; Mwasongwe S; Carr JJ; Terry JG; Mentz RJ; Addison D; Hoffmann U; Reis J; Freedman JE; Lima JAC; Correa A; Murthy VL
    JAMA Cardiol; 2017 Jun; 2(6):644-652. PubMed ID: 28315622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Statins for Primary Prevention: Selection of Risk Threshold and Implications Across Race and Gender.
    Goyal A; Cooper HA; Aronow WS; Nagpal P; Yandrapalli S; Nabors CC; Frishman WH
    Am J Med; 2018 Oct; 131(10):1234-1237. PubMed ID: 29928863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat.
    Mortensen MB; Nordestgaard BG
    JAMA Cardiol; 2019 Nov; 4(11):1131-1138. PubMed ID: 31577339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines.
    Mortensen MB; Tybjærg-Hansen A; Nordestgaard BG
    JAMA Cardiol; 2022 Aug; 7(8):836-843. PubMed ID: 35793078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Race and Socioeconomic Differences Associated With Changes in Statin Eligibility Under the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Verma AA; Jimenez MP; Subramanian SV; Sniderman AD; Razak F
    Circ Cardiovasc Qual Outcomes; 2017 Sep; 10(9):. PubMed ID: 28912201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States.
    Lee JC; Zdrojewski T; Pencina MJ; Wyszomirski A; Lachacz M; Opolski G; Bandosz P; Rutkowski M; Gaciong Z; Wyrzykowski B; Navar AM
    JAMA Cardiol; 2016 Sep; 1(6):700-7. PubMed ID: 27434662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicted Cardiovascular Risk by the PREVENT Equations in US Adults With Stage 1 Hypertension.
    Muntner P; Jaeger BC; Foti K; Ghazi L; Bundy JD; Chen L; Safford MM
    Hypertension; 2024 Sep; 81(9):1976-1985. PubMed ID: 39005226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes.
    McEvoy JW; Daya N; Rahman F; Hoogeveen RC; Blumenthal RS; Shah AM; Ballantyne CM; Coresh J; Selvin E
    JAMA; 2020 Jan; 323(4):329-338. PubMed ID: 31990314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy.
    Mortensen MB; Afzal S; Nordestgaard BG; Falk E
    J Am Coll Cardiol; 2015 Dec; 66(24):2699-2709. PubMed ID: 26700832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.
    Jacobs JA; Addo DK; Zheutlin AR; Derington CG; Essien UR; Navar AM; Hernandez I; Lloyd-Jones DM; King JB; Rao S; Herrick JS; Bress AP; Pandey A
    JAMA Cardiol; 2023 May; 8(5):443-452. PubMed ID: 36947031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.